SiSaf Overview
- Year Founded
-
2006
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$17.9M
- Investors
-
11
SiSaf General Information
Description
Developer of a biomaterial-based drug delivery platform designed to improve the delivery of RNA therapeutics and other therapeutic molecules. The company offers a bioabsorbable silicon matrix combined with lipids and amino acids to enhance stability, solubility, targeting, transfection efficiency, and controlled release, enabling biotechnology and pharmaceutical companies to develop therapies across diverse disease indications.
Contact Information
Website
www.sisaf.comCorporate Office
- 6-8 Frederick Sanger Road
- Guildford GU2 7YD
- England, United Kingdom
Corporate Office
- 6-8 Frederick Sanger Road
- Guildford GU2 7YD
- England, United Kingdom
SiSaf Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Later Stage VC (Series B) | 04-Apr-2023 | $17.9M | Completed | Generating Revenue | ||
| 11. Grant | 01-Jan-2021 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series A3) | 31-Jul-2019 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 01-Aug-2018 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A2) | 31-May-2018 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series A1) | 01-Aug-2017 | Completed | Generating Revenue | |||
| 6. Grant | 01-Oct-2016 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2016 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 18-Oct-2013 | $676K | $872K | Completed | Generating Revenue | |
| 3. Angel (individual) | 11-Mar-2011 | $60.5K | $196K | Completed | Generating Revenue |
SiSaf Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A3 | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A2 | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A1 | 359,625 | $0.000122 | $3.55 | $3.55 | 1x | $3.55 | 7.15% | |
| Series A1 | 119,875 | $0.000122 | $3.51 | $3.51 | 1x | $3.51 | 2.38% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SiSaf Comparisons
Industry
Financing
Details
SiSaf Competitors (4)
One of SiSaf’s 4 competitors is Acuitas Therapeutics, a Corporation company based in Vancouver, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Acuitas Therapeutics | Corporation | Vancouver, Canada | ||||
| Stoke Therapeutics | Formerly VC-backed | Bedford, MA | ||||
| Avanti Research | Corporate Backed or Acquired | Alabaster, AL | ||||
| Avenir Wellness Solutions | Formerly VC-backed | Oxnard, CA |
SiSaf Patents
SiSaf Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202511471-D0 | Exosome-based compositions | Pending | 15-Jul-2025 | ||
| GB-202511472-D0 | Opthalmic delivery of exosome compositions | Pending | 15-Jul-2025 | ||
| GB-202402999-D0 | Medicinal products and uses thereof | Inactive | 01-Mar-2024 | ||
| WO-2025181500-A1 | Mirna composition accumulating in pancreas and/or spleen | Pending | 01-Mar-2024 | ||
| GB-202300914-D0 | Manufacturing process | Inactive | 20-Jan-2023 | A61K9/1271 |
SiSaf Signals
SiSaf Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Future Fund (UK) | Lender/Debt Provider | Minority | ||
| Croda International | Corporation | Minority | ||
| Vickers Venture Partners | Corporate Venture Capital | Minority | ||
| Innovate UK | Government | |||
| Clarendon Fund Managers | Venture Capital | Minority |
SiSaf FAQs
-
When was SiSaf founded?
SiSaf was founded in 2006.
-
Where is SiSaf headquartered?
SiSaf is headquartered in Guildford, United Kingdom.
-
What is the size of SiSaf?
SiSaf has 18 total employees.
-
What industry is SiSaf in?
SiSaf’s primary industry is Drug Discovery.
-
Is SiSaf a private or public company?
SiSaf is a Private company.
-
What is the current valuation of SiSaf?
The current valuation of SiSaf is .
-
What is SiSaf’s current revenue?
The current revenue for SiSaf is .
-
How much funding has SiSaf raised over time?
SiSaf has raised $43.3M.
-
Who are SiSaf’s investors?
Future Fund (UK), Croda International, Vickers Venture Partners, Innovate UK, and Clarendon Fund Managers are 5 of 11 investors who have invested in SiSaf.
-
Who are SiSaf’s competitors?
Acuitas Therapeutics, Stoke Therapeutics, Avanti Research, and Avenir Wellness Solutions are competitors of SiSaf.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process